Why Is Cancer Treatment Different for Every Patient?
In this article
The Quiet Factors That Change Cancer Treatment Decisions
Cancer treatment is not chosen solely on the basis of stage, tumor type or guidelines. Often, the treatment decision is determined by quiet clinical factors that appear in the small print of reports but can fundamentally change the outcome.
These seemingly ‘hidden’ factors often explain why two patients with the same diagnosis and stage receive completely different treatments. Treatment decisions take shape within the triangle of tumor + patient + time .
Why are they invisible?
They are not explicitly stated in radiology and pathology reports; they emerge during clinical assessment.
Why are they decisive?
They change the treatment’s benefit–risk balance, its dose and even whether it should be given at all.
Clinical reality
Ignoring these factors can produce decisions that are ‘appropriate according to the guidelines, but inappropriate for the patient’.
Performance Status: A Stronger Determinant Than Age
One of the quietest yet most powerful factors affecting treatment decisions is performance status(ECOG / Karnofsky). Two patients of the same age can have entirely different performance profiles.
Good performance status: More intensive treatments, combination regimens and aggressive approaches may be tolerated.
Poor performance status: The same treatment may cause severe toxicity, hospitalization or early treatment discontinuation.
An ‘80-year-old but active’ patient and a ‘60-year-old but bedridden’ patient therefore require entirely different treatment approaches.
Comorbidities and Frailty
Conditions such as diabetes, heart failure, COPD, kidney failure or liver failure quietly alter treatment selection, dosing and sequencing .
In frail patients, the problem is often not ‘the cancer itself’ but the inability to tolerate treatment. Sometimes, therefore, milder but sustainable treatments provide more benefit than aggressive approaches.
Kidney and Liver Function
Even when laboratory values appear ‘mildly abnormal’, the time many drugs remain in the body and their toxicity profiles may change dramatically.
- Kidney function: Determines dosing for platinum agents, some targeted agents and supportive treatments.
- Liver function: May increase the risk of severe adverse effects with drugs that are metabolized.
For some patients, therefore, instead of ‘the standard dose in the guidelines’, an individualized dose or a completely different treatment option is preferred.
The Tumor’s Biological Behavior (Same Stage, Different Behavior)
Staging describes tumor burden; biology shows how aggressively the tumor behaves. Two tumors at the same stage may progress at entirely different speeds.
- Proliferation rate (markers such as Ki-67)
- Pattern of metastasis (oligometastatic vs. widespread)
- Duration of response to previous treatments
With indolent biology, the aim may be long-term control; with aggressive biology, rapid and potent systemic treatments take priority.
The Patient’s Priorities and Life Goals
One of the least discussed factors that changes treatment decisions is what the patient wants.
- Is length of life or quality of life the priority?
- Are frequent hospital visits acceptable?
- How much risk of adverse effects is tolerable?
In the same clinical situation, one person may choose more aggressive treatment while another prefers a gentler approach. Both decisions may be right .
Timing: When You Start Treatment
The treatment decision is not only a question of ‘what’; it is also a question of ‘when’ .
- At the time of a new diagnosis
- During a period with minimal symptoms
- During rapid clinical deterioration
The same treatment can produce entirely different outcomes when given at different times.
Psychosocial Factors and Social Support
Social support plays a critical role in treatment adherence and sustainability. Complex treatment regimens may become impractical for patients living alone without caregiving support.
A treatment may be right ‘on paper’; but if the patient cannot sustain it, it is not right in real life.
Quiet Factors Shape Treatment Decisions
Decisions in cancer treatment are based not only on tumor stage, but also on the patient’s biology, resilience, expectations and living conditions .
The best treatment is not simply ‘what the guidelines say’; it is treatment chosen for that patient at the right time, at the right dose and for the right purpose .
References
- ESMO Clinical Practice Guidelines – Treatment decision-making in oncology.
- NCCN Guidelines – Patient selection and performance status considerations.
- Balducci L. Geriatric oncology: challenges for the new century.
- ASCO Educational Book – Shared decision-making in cancer care.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.